O

Option Care Health

Largest independent home infusion therapy provider

Clinical Pharmacist

Full-TimeUpdated on 10/23/2026
$60.82 - $101.38
Entry
Bachelor's
San Diego, CA, USA
In PersonTravel up to 5% of the time within the state.
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • Graduate of an accredited School of Pharmacy.
  • Hold a current, active pharmacy license granted by the State Board of Pharmacy.
  • Meet one of the following: at least one year of experience in sterile intravenous admixture procedures; knowledge of non-sterile compounding, immunizations, and medication therapy management; completion of an ASHP-accredited Pharmacy Residency Program; completion of an Advanced Pharmacy Practice Experience associated with an accredited school of pharmacy; or equivalent experience approved by the Vice President of Pharmacy and/or Senior Vice President of Clinical Services.
  • Have access to reliable transportation to make home visits. If using a personal vehicle, hold a valid driver's license and provide proof of insurance.
  • Have experience providing customer service to internal and external customers, including meeting service quality standards and evaluating customer satisfaction.
  • Have basic-level skill in Microsoft Word, including opening documents; cutting, pasting, and aligning text; selecting font type and size; changing margins and column width; sorting; inserting bullets, pictures, and dates; using find and replace, undo, spell check, track changes, the review pane, and print functions.
  • Have basic-level skill in Microsoft Excel, including opening workbooks; inserting rows and columns; selecting font style and size; formatting cells as currency; copying, pasting, and saving; aligning text; selecting cells; renaming worksheets; choosing chart styles; inserting worksheets; setting margins and page orientation; spell-checking; and printing worksheets.
  • Have basic-level skill in Microsoft PowerPoint, including inserting, rearranging, hiding, and deleting slides; navigating between slides; increasing list level; adding, centering, and editing text; changing views; inserting tables or notes; moving objects; printing outline view; and running slide shows.
  • Be willing to travel up to 5% of the time for business purposes within the state.
  • Have at least one year of experience in indirect management of team members, including assisting with their development, training, and assignment of work or projects.
Responsibilities
  • Determine patients' suitability for home care by collecting and organizing patient-specific information, assessing suitability under company policies, and evaluating whether the medical condition and prescribed therapy are appropriate for home care with a prognosis and clearly defined outcome goals.
  • Design, recommend, monitor, and evaluate patient-specific pharmacy care plans for home-care pharmacotherapy; recommend medication-therapy or monitoring-parameter modifications when appropriate; collect information to prevent, detect, and resolve medication-related problems; identify appropriate monitoring parameters; and complete nutritional assessments with appropriate recommendations.
  • Modify pharmacy care plans based on monitoring data and other relevant patient-specific information; apply pharmacokinetic principles and formulas; and assess patient laboratory values.
  • Provide medication-use education to company staff, other professionals, patients, and caregivers, using effective patient-education techniques to counsel patients and caregivers.
  • Ensure continuity of pharmaceutical care between home and other patient-care settings by communicating pertinent patient information; prepare and dispense medications using appropriate techniques and company procedures; calibrate equipment; prepare medications at appropriate concentrations and ensure they are compatible, stable, and properly stored; follow safety and quality-assurance practices; prepare compliant labels and ancillary labels; inspect medications before dispensing; confirm authorization to dispense; comply with applicable state and federal laws, United States Pharmacopeia standards, and Drug Enforcement Administration controlled-substance regulations; and follow perpetual-inventory policies for Schedule II narcotics, controlled substances, and other medications subject to diversion.
  • Manage the use, maintenance, and troubleshooting of medication-administration and related equipment; program and maintain equipment and advise others on its use and maintenance; participate in assessing, managing, and reporting medication-related incidents and equipment errors or failures; complete quality assurance reports according to policy; and monitor and report perpetual-inventory discrepancies for Schedule II narcotics and other medications subject to diversion.
  • Respond concisely, appropriately, and promptly to drug-information requests from healthcare providers and patients; formulate responses based on literature analysis; and maintain professional competency by attending educational seminars or participating in continuing-education opportunities and meeting state continuing-education requirements.
  • Manage investigational drug products according to regulations and company policies; use pharmacy support personnel effectively; prioritize and organize workflow based on available resources; complete required work within the time available; and ensure the accuracy of pharmacy support personnel's work.
  • Comply with accreditation, legal, regulatory, and safety requirements in all activities.
  • Maintain confidentiality of patient and proprietary information and follow legal and ethical guidelines for safeguarding that information.
  • Perform other duties as assigned.
Desired Qualifications
  • Completion of an ASHP-accredited Pharmacy Residency Program or an Advanced Pharmacy Practice Experience associated with an accredited school of pharmacy.
  • Experience in home care, a hospital, or another clean-room setting.

About the company

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Bannockburn, Illinois

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 29, 2026 Q2 revenue reached $1.44 billion, while acute therapy and IG Neuro strengthened.
  • Management stabilized CID patient census in Q2 2026 and kept full-year revenue guidance unchanged.
  • The company repurchased $150 million in Q2 2026, signaling confidence and shareholder-return capacity.

What critics are saying

  • August 2026 guidance still bakes in a 600-basis-point CID revenue headwind and $55 million gross profit hit.
  • July 29, 2026 Q2 buyback of $150 million masks weak top-line momentum and analyst skepticism.
  • Biosimilar erosion and payer reverification pressure can permanently shrink chronic volumes if retention stays broken.

What makes Option Care Health unique

  • Option Care Health leads U.S. independent home and alternate-site infusion, with nationwide clinician density.
  • Its payer, biopharma, and prescriber relationships create switching costs across chronic and acute therapies.
  • August 27, 2026 guidance shows durable cash generation, with at least $320 million operating cash flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Time Off
  • Bonding Time Off
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Health Savings Account/Flexible Spending Account
  • Flexible Spending Accounts
  • Tuition Reimbursement
  • Family Support
  • Mental Health Support

Company News

American Market News
Oct 23rd, 2026
Option Care Health, Inc. $OPCH holdings increased by Isthmus Partners LLC.

Option Care Health, Inc. $OPCH holdings increased by Isthmus Partners LLC. Posted by ABMN Staff on Oct 23rd, 2026 Isthmus Partners LLC boosted its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 37.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 169,172 shares of the company's stock after acquiring an additional 46,518 shares during the period. Isthmus Partners LLC owned 0.11% of Option Care Health worth $3,805,000 at the end of the most recent reporting period. A number of other hedge funds have also added to or reduced their stakes in the stock. Reyes Financial Architecture Inc. purchased a new position in shares of Option Care Health during the third quarter valued at about $28,000. Pinnacle Associates Ltd. lifted its holdings in Option Care Health by 1.8% in the third quarter. Pinnacle Associates Ltd. now owns 20,355 shares of the company's stock worth $458,000 after buying an additional 354 shares during the period. Nisa Investment Advisors LLC boosted its position in Option Care Health by 268.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,955 shares of the company's stock valued at $66,000 after acquiring an additional 2,154 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Option Care Health by 5.1% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,421,567 shares of the company's stock worth $31,971,000 after acquiring an additional 68,572 shares during the period. Finally, Central Pacific Bank Trust Division grew its holdings in shares of Option Care Health by 3.9% during the 3rd quarter. Central Pacific Bank Trust Division now owns 14,369 shares of the company's stock worth $323,000 after acquiring an additional 540 shares during the period. 98.05% of the stock is owned by hedge funds and other institutional investors. Option Care Health stock performance. Shares of Option Care Health stock opened at $31.29 on Friday. The business has a 50-day moving average of $25.57 and a 200 day moving average of $23.84. Option Care Health, Inc. has a 12 month low of $18.01 and a 12 month high of $36.80. The stock has a market capitalization of $4.69 billion, a price-to-earnings ratio of 19.80, a price-to-earnings-growth ratio of 1.90 and a beta of 0.58. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.47 and a quick ratio of 0.98. Discover more Read Daily News Option Care Health (NASDAQ:OPCH - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The company had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.42 billion. Option Care Health had a return on equity of 18.74% and a net margin of 3.68%. Option Care Health's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.41 EPS. Option Care Health has set its FY 2026 guidance at 1.850-1.920 EPS. As a group, sell-side analysts forecast that Option Care Health, Inc. will post 1.70 earnings per share for the current year. Wall street analysts forecast growth. Several brokerages have recently issued reports on OPCH. Jefferies Financial Group lowered Option Care Health from a "buy" rating to a "hold" rating and increased their target price for the stock from $28.00 to $32.05 in a research report on Tuesday, October 6th. Barrington Research lowered shares of Option Care Health from an "outperform" rating to a "hold" rating in a research report on Wednesday, October 7th. UBS Group lowered Option Care Health from a "buy" rating to a "neutral" rating and dropped their target price for the company from $39.00 to $32.05 in a research report on Friday, October 9th. Morgan Stanley set a $32.05 price target on shares of Option Care Health in a research report on Monday, October 12th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $33.00 price target on shares of Option Care Health in a research note on Wednesday, October 7th. Two investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Option Care Health presently has an average rating of "Hold" and an average price target of $29.48. About Option Care Health. Option Care Health, Inc is an independent provider of home and alternate-site infusion services in the United States. The company coordinates and delivers infusion therapy outside traditional hospital settings, including patients' homes, ambulatory infusion suites and other outpatient locations. Its services include administration of anti-infective therapies, immune globulin, nutrition support, inotropic therapies and medications used in the treatment of chronic and complex conditions. Want to see what other hedge funds are holding OPCH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Option Care Health, Inc. (NASDAQ:OPCH - Free Report). Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.

AD HOC NEWS
Oct 15th, 2026
McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

Yahoo Finance
Oct 6th, 2026
McKesson and Clayton Dubilier & Rice near $5B deal to acquire Option Care Health

Option Care Health shares jumped 33.2% in pre-market trading after the Financial Times reported McKesson and Clayton Dubilier & Rice are nearing a transaction valued at over $5 billion to acquire the alternate site health provider. According to the report, the deal would involve the two firms partnering to buy the infusion services provider, which they view as undervalued. Large-scale buyout discussions typically drive market optimism as investors anticipate acquisition premiums. The move is significant for Option Care Health, whose shares have experienced 13 movements greater than 5% over the past year. At $31.03 per share, the stock is trading 15.2% below its 52-week high but remains down 3.8% year-to-date.

Central Charts
Oct 6th, 2026
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have

Yahoo Finance
Jul 29th, 2026
Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.